Patient number | Age | APS/SLE | Treatment | aPL at screening | Pregnancy duration | APOs |
---|---|---|---|---|---|---|
1 | 27 | SLE | ASA, HEP (low dose) | LAC | 23.6 WG | Fetal death |
2 | 29 | Thrombotic APS | ASA, HEP (full dose) IVIG | LAC aCL IgG aβ2GPI IgG | 29.4 WG | Atypical HELLP and severe pre-eclampsia |
3 | 39 | Thrombotic APS | ASA, HEP (full dose) HCQ | LAC aCL IgG/IgM aβ2GPI IgG | 38.1 WG | SGA |
4 | 38 | Thrombotic APS | ASA, HEP (full dose) HCQ | LAC aCL IgG aβ2GPI IgG | 17.4 WG | Fetal death |
5 | 39 | SLE | ASA | LAC | 39.2 WG | SGA |
6 | 33 | Obstetrical APS | ASA, HEP (full dose) HCQ | aCL IgG aβ2GPI IgG | 29.3 WG | Superimposed severe pre-eclampsia, IUGR and birth weight <10th percentile |
7 | 33 | Obstetrical APS | ASA, HEP (low dose) | 32.1 WG | Pre-eclampsia | |
8 | 34 | Thrombotic APS | ASA, HEP (full dose) | LAC aCL IgG aβ2GPI IgG | 18.2 WG | Fetal death |
9 | 35 | SLE thrombotic APS | ASA, HEP (low dose) HCQ | LAC | 26.4 WG | HELLP |
10 | 23 | Thrombotic APS | HEP (full dose) HCQ | aCL IgG aβ2GPI IgG | 38.2 WG | SGA |
11 | 32 | Thrombotic APS | HEP (full dose) | aCL IgG aβ2GPI IgG | 32.4 WG | Gestational hypertension, placental insufficiency and SGA |
12 | 22 | SLE thrombotic APS | HEP (full dose) Steroids HCQ | LAC aCL IgG aβ2GPI IgG | 20.3 WG | Preterm delivery, fetal demise due to HELLP syndrome |
13 | 35 | Thrombotic APS | ASA, HEP (full dose) | LAC aCL IgG | 17.6 WG | Fetal death |
aCL, anticardiolipin antibodies; aPL, antiphospholipid antibodies; APOs, adverse pregnancy outcomes; APS, antiphospholipid syndrome; ASA, aspirin; aβ2GPI, anti-β2 glycoprotein I antibodies; HCQ, hydroxychloroquinine; HELLP, haemolysis elevated liver enzyme and low platelet count syndrome; HEP, low molecular weight heparin; IUGR, intrauterine growth restriction; IVIG, intravenous immunoglobulin therapy; LAC, lupus anticoagulant; SGA, small for gestational age neonate (birth weight below the fifth percentile); SLE, systemic lupus erythematosus; WG, weeks of gestation.